Asher Bio Announces Clinical Supply Agreement With AstraZeneca To Enable Evaluation Of Etakafusp Alfa In Combination With Rilvegostomig In A Global Phase 1b/2 Study In Non-Small Cell Lung Cancer
Asher Bio Announces Clinical Supply Agreement With AstraZeneca To Enable Evaluation Of Etakafusp Alfa In Combination With Rilvegostomig In A Global Phase 1b/2 Study In Non-Small Cell Lung Cancer
– Clinical supply agreement with AstraZeneca for global Phase 1b/2 study to evaluate the safety and early efficacy of etakafusp alfa (AB248) in combination with rilvegostomig as a first-line treatment in patients with advanced or metastatic NSCLC –
– 與阿斯利康簽署的臨牀供應協議，旨在進行全球I期b/II期研究，以評估etakafusp ALFA（AB248）與rilvegostomig聯合使用作爲晚期或轉移性非小細胞肺癌(NSCLC)患者的頭號治療的安全性和早期療效 –
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an agreement with AstraZeneca (NASDAQ:AZN) to supply etakafusp alfa (formerly known as AB248), Asher Bio's investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, to be evaluated in combination with rilvegostomig, AstraZeneca's investigational PD-1/TIGIT immuno-oncology bispecific antibody, in patients with advanced or metastatic NSCLC.
Asher生物治療公司是一家開發針對癌症和傳染病的精確靶向免疫療法的生物技術公司，今天宣佈與阿斯利康（納斯達克：AZN）簽署協議，提供etakafusp ALFA（前稱AB248），這是Asher Bio的實驗性CD8+ T細胞靶向白介素-2（IL-2）免疫療法，將與阿斯利康的實驗性PD-1/TIGIt免疫腫瘤雙特異性抗體聯合使用，評估其在晚期或轉移性非小細胞肺癌(NSCLC)患者中的效果。
譯文內容由第三人軟體翻譯。